Economic impact of introducing TYRX amongst patients with heart failure and reduced ejection fraction undergoing implanted cardiac device procedures: a retrospective model based cost analysis

TY - JOUR

T1 - Economic impact of introducing TYRX amongst patients with heart failure and reduced ejection fraction undergoing implanted cardiac device procedures

T2 - a retrospective model based cost analysis

AU - Burnhope, Emma

AU - Rodriguez-Guadarrama, Yael

AU - Waring, Michael

AU - Guilder, Andrew

AU - Malhotra, Bharti

AU - Razavi, Reza

AU - Rinaldi, Aldo

AU - Pennington, Mark

AU - Carr-White, Gerald

PY - 2019/5/4

Y1 - 2019/5/4

N2 - BACKGROUND AND AIMS: Infection is a serious and expensive complication of Cardiac Implantable Electronic Device (CIED) procedures. We performed a retrospective based cost analysis to estimate Trust level savings of using the TYRX antibacterial envelope as a primary prevention measure against infection in a tertiary referral centre in South London, United Kingdom.METHODS: A retrospective cohort of heart failure patients with reduced ejection fraction undergoing Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT) procedures were evaluated. Decision-analytic modelling was performed to determine economic savings of using the envelope during CIED procedure versus CIED procedure alone.RESULTS: Over a 12 month follow-up period following CIED procedure the observed infection rate was 3.14% (n = 5/159). The average cost of a CIED infection inpatient admission was £41,820 and further to economic analysis, the additional costs attributable to infection was calculated at £62,213.94. A cost saving of £624 per patient by using TYRX during CIED procedure as a primary preventative measure against infection was estimated.CONCLUSIONS: TYRX would be a cost-saving treatment option amongst heart failure patients undergoing ICD and CRT device procedures based on analysis in the local geographical area of South London. If upscaled to the UK population, we estimate potential cost savings for the National Health Service (NHS).

AB - BACKGROUND AND AIMS: Infection is a serious and expensive complication of Cardiac Implantable Electronic Device (CIED) procedures. We performed a retrospective based cost analysis to estimate Trust level savings of using the TYRX antibacterial envelope as a primary prevention measure against infection in a tertiary referral centre in South London, United Kingdom.METHODS: A retrospective cohort of heart failure patients with reduced ejection fraction undergoing Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT) procedures were evaluated. Decision-analytic modelling was performed to determine economic savings of using the envelope during CIED procedure versus CIED procedure alone.RESULTS: Over a 12 month follow-up period following CIED procedure the observed infection rate was 3.14% (n = 5/159). The average cost of a CIED infection inpatient admission was £41,820 and further to economic analysis, the additional costs attributable to infection was calculated at £62,213.94. A cost saving of £624 per patient by using TYRX during CIED procedure as a primary preventative measure against infection was estimated.CONCLUSIONS: TYRX would be a cost-saving treatment option amongst heart failure patients undergoing ICD and CRT device procedures based on analysis in the local geographical area of South London. If upscaled to the UK population, we estimate potential cost savings for the National Health Service (NHS).

KW - Infection

KW - TYRX envelope

KW - cardiac implantable electronic device

KW - economic model

KW - healthcare costs

UR - http://www.scopus.com/inward/record.url?scp=85064323997&partnerID=8YFLogxK

U2 - 10.1080/13696998.2019.1581621

DO - 10.1080/13696998.2019.1581621

M3 - Article

C2 - 30744444

SN - 1369-6998

VL - 22

SP - 464

EP - 470

JO - Journal of medical economics

JF - Journal of medical economics

IS - 5

ER -